SLC5A2 and chronic kidney disease: Finerenone’s renal benefits were dose-dependent up to ~20 mg/day, with effects approaching saturation at this dose. No clinically relevant PK covariates altered outcomes. SGLT2 inhibitor co-use independently lowered CKD progression risk but did not modify finerenone’s effect.